Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Professor Chan Cheah has co-authored an important manuscript on the phase IIB trial UNITY-NHL in the Journal in Clinical Oncology which evaluates the efficacy and safety of a phophatidylynositol-3-kinase (PI3K) inhibitor umbralisib in patients with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma. Umbralisib showed meaningful clinical activity in this group of patients and consistent with that demonstrated by prior inhibitors of PI3K. The safety profile appears improved compared with first-generation PI3K inhibitors, with manageable toxicities and a relatively low number of adverse event-related discontinuations. These results suggest that umbralisib has a favourable benefit-risk profile in this heavily pretreated population.

Umbralisib has been granted approval from the Food and Drug Administration for patients with marginal zone lymphoma that has returned or worsened following prior treatment and also approved for follicular lymphoma patients who have failed 3 prior systemic therapies.

Full manuscript available here: